Compare MakeMyTrip Ltd (MMYT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Spyre Therapeutics Inc. Common Stock — how do they compare? MakeMyTrip Ltd trades at $43.7 (market cap $4.21B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MMYT | SYRE | |
|---|---|---|
Market Cap | $4.21B | $7.52B |
Volume | 954,905 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.73 | $108.92 |
52-Week Low | $36.30 | $22.18 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $4.87B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $44.70, showing modest daily gains of 0.81%. The stock faces bearish technical signals with mixed earnings performance - beating Q1 2026 estimates but missing Q4 2025 and Q2 2026. Revenue growth remains positive with $978M in 2025, though profitability metrics show volatility. Analyst sentiment remains strongly bullish with a $77 consensus target representing 72% upside potential.
The stock presents significant upside based on analyst targets but faces execution risks amid volatile earnings and rising debt levels. Key catalysts include the planned Indian listing and operational resilience, while risks include geopolitical disruptions and competitive pressures in the travel sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
